The ATG5-Binding and Coiled Coil Domains of ATG16L1 Maintain
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
ATG5 Mediates a Positive Feedback Loop Between Wnt Signaling and Autophagy In
Author Manuscript Published OnlineFirst on September 8, 2017; DOI: 10.1158/0008-5472.CAN-17-0907 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. ATG5 mediates a positive feedback loop between Wnt signaling and autophagy in melanoma Abibatou Ndoye1,2, Anna Budina-Kolomets1,3, Curtis H. Kugel III1, Marie Webster1, Amanpreet Kaur1,2, Reeti Behera1, Vito Rebecca3, Ling Li1, Patricia Brafford1, Qin Liu1, Y.N. Vashisht Gopal4, Michael A. Davies4, Gordon B. Mills4, Xiaowei Xu3, Hong Wu5, Meenhard Herlyn1, Michael Nicastri3, Jeffrey Winkler3, Maria S. Soengas6, Ravi Amaravadi3, Maureen Murphy1, and Ashani T. Weeraratna1* 1The Wistar Institute Melanoma Research Center, Philadelphia, PA, 19104, 2The University of the Sciences, Philadelphia, PA, 19104, 3The University of Pennsylvania, Philadelphia PA, 19104, 4The University of Texas MD Anderson Cancer Center, Houston, TX, 77050, and 5Melanoma Group, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain *To Whom Correspondence Should Be Addressed: Ashani T. Weeraratna, Ph.D. The Wistar Institute 3601 Spruce Street Philadelphia, PA 19104 Office: 215 495-6937 Email: [email protected] KEYWORDS: Wnt5A, autophagy, melanoma, lysosome, cellular homeostasis FINANCIAL SUPPORT: A.T. Weeraratna, A. Kaur, and R. Behera are supported by R01CA174746. A. Ndoye, A. Budina-Kolomets, V.W. Rebecca, M. Murphy, R. Amaravadi and A.T. Weeraratna. are supported by P01 CA114046 and A Ndoye, A.T. Weeraratna and R Amaravadi are also supported by P50CA174523. CH Kugel III is supported by T32CA009171. M.R. Webster is supported by K99 CA208012-01. R. Amaravadi is supported by R01CA169134M. Soengas and AT Weeraratna are also supported by a Melanoma Research Alliance/ L’Oréal Paris-USA Women in Science Team Science Award. -
Autophagy Promotes Hepatic Differentiation of Hepatic Progenitor Cells by Regulating the Wnt/Β-Catenin Signaling Pathway
Journal of Molecular Histology (2019) 50:75–90 https://doi.org/10.1007/s10735-018-9808-x ORIGINAL PAPER Autophagy promotes hepatic differentiation of hepatic progenitor cells by regulating the Wnt/β-catenin signaling pathway Zhenzeng Ma1 · Fei Li1 · Liuying Chen1 · Tianyi Gu1 · Qidi Zhang1 · Ying Qu1 · Mingyi Xu1 · Xiaobo Cai1 · Lungen Lu1 Received: 25 September 2018 / Accepted: 7 December 2018 / Published online: 2 January 2019 © The Author(s) 2019 Abstract Hepatic progenitor cells (HPCs) can be activated when the liver suffers persistent and severe damage and can differenti- ate into hepatocytes to maintain liver regeneration and homeostasis. However, the molecular mechanism underlying the hepatic differentiation of HPCs is unclear. Therefore, in this study, we aimed to investigate the roles of autophagy and the Wnt/β-catenin signaling pathway during hepatic differentiation of HPCs in vivo and in vitro. First, immunohistochemistry, immunofluorescence and electron microscopy showed that Atg5 and β-catenin were highly expressed in human fibrotic liver and mouse liver injury induced by feeding a 50% choline-deficient diet plus 0.15% ethionine solution in drinking water (CDE diet) for 21 days; in addition, these factors were expressed in CK19-positive HPCs. Second, Western blotting and immunofluorescence confirmed that CK19-positive HPCs incubated in differentiation medium for 7 days can differentiate into hepatocytes and that differentiated HPCs were able to take up ICG and secrete albumin and urea. Further investigation via Western blotting, immunofluorescence and electron microscopy revealed autophagy and the Wnt/β-catenin pathway to be activated during hepatic differentiation of HPCs. Next, we found that inhibiting autophagy by downregulating Atg5 gene expression impaired hepatic differentiation of HPCs and inhibited activation of the Wnt/β-catenin pathway, which was rescued by overexpression of the β-catenin gene. -
Wnt/Β-Catenin Signaling Pathway Induces Autophagy
Yun et al. Cell Death and Disease (2020) 11:771 https://doi.org/10.1038/s41419-020-02988-8 Cell Death & Disease ARTICLE Open Access Wnt/β-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma Eun-Jin Yun 1,SangwooKim2,Jer-TsongHsieh3,4 and Seung Tae Baek 5,6 Abstract Temozolomide (TMZ) is widely used for treating glioblastoma multiforme (GBM), however, the treatment of such brain tumors remains a challenge due to the development of resistance. Increasing studies have found that TMZ treatment could induce autophagy that may link to therapeutic resistance in GBM, but, the precise mechanisms are not fully understood. Understanding the molecular mechanisms underlying the response of GBM to chemotherapy is paramount for developing improved cancer therapeutics. In this study, we demonstrated that the loss of DOC-2/DAB2 interacting protein (DAB2IP) is responsible for TMZ-resistance in GBM through ATG9B. DAB2IP sensitized GBM to TMZ and suppressed TMZ-induced autophagy by negatively regulating ATG9B expression. A higher level of ATG9B expression was associated with GBM compared to low-grade glioma. The knockdown of ATG9B expression in GBM cells suppressed TMZ-induced autophagy as well as TMZ-resistance. Furthermore, we showed that DAB2IP negatively regulated ATG9B expression by blocking the Wnt/β-catenin pathway. To enhance the benefit of TMZ and avoid therapeutic resistance, effective combination strategies were tested using a small molecule inhibitor blocking the Wnt/ β-catenin pathway in addition to TMZ. The combination treatment synergistically enhanced the efficacy of TMZ in GBM cells. In conclusion, the present study identified the mechanisms of TMZ-resistance of GBM mediated by DAB2IP 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; and ATG9B which provides insight into a potential strategy to overcome TMZ chemo-resistance. -
Autophagy Suppresses Ras-Driven Epithelial Tumourigenesis by Limiting the Accumulation of Reactive Oxygen Species
OPEN Oncogene (2017) 36, 5576–5592 www.nature.com/onc ORIGINAL ARTICLE Autophagy suppresses Ras-driven epithelial tumourigenesis by limiting the accumulation of reactive oxygen species This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue. J Manent1,2,3,4,5,12, S Banerjee2,3,4,5, R de Matos Simoes6, T Zoranovic7,13, C Mitsiades6, JM Penninger7, KJ Simpson4,5, PO Humbert3,5,8,9,10 and HE Richardson1,2,5,8,11 Activation of Ras signalling occurs in ~ 30% of human cancers; however, activated Ras alone is not sufficient for tumourigenesis. In a screen for tumour suppressors that cooperate with oncogenic Ras (RasV12)inDrosophila, we identified genes involved in the autophagy pathway. Bioinformatic analysis of human tumours revealed that several core autophagy genes, including GABARAP, correlate with oncogenic KRAS mutations and poor prognosis in human pancreatic cancer, supporting a potential tumour- suppressive effect of the pathway in Ras-driven human cancers. In Drosophila, we demonstrate that blocking autophagy at any step of the pathway enhances RasV12-driven epithelial tissue overgrowth via the accumulation of reactive oxygen species and activation of the Jun kinase stress response pathway. Blocking autophagy in RasV12 clones also results in non-cell-autonomous effects with autophagy, cell proliferation and caspase activation induced in adjacent wild-type cells. Our study has implications for understanding the interplay between perturbations in Ras signalling and autophagy in tumourigenesis, -
ATG5 Antibody (N-Term) Purified Rabbit Polyclonal Antibody (Pab) Catalog # Ap1812a
10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 ATG5 Antibody (N-term) Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP1812a Specification ATG5 Antibody (N-term) - Product Information Application IF, WB, IHC-P-Leica,E Primary Accession Q9H1Y0 Other Accession Q3MQ06, Q3MQ04, Q99J83, Q3MQ24, Q6DEM4 Reactivity Human Predicted Zebrafish, Bovine, Mouse, Pig, Rat Host Rabbit Clonality Polyclonal Isotype Rabbit Ig Antigen Region 1-30 ATG5 Antibody (N-term) - Additional Information Fluorescent image of U251 cells stained with Gene ID 9474 ATG5 (N-term) antibody. U251 cells were treated with Chloroquine (50 μM,16h), then Other Names fixed with 4% PFA (20 min), permeabilized Autophagy protein 5, APG5-like, with Triton X-100 (0.2%, 30 min). Cells were Apoptosis-specific protein, ATG5, APG5L, then incubated with AP1812a ATG5 (N-term) ASP primary antibody (1:200, 2 h at room temperature). For secondary antibody, Alexa Target/Specificity Fluor® 488 conjugated donkey anti-rabbit This ATG5 antibody is generated from antibody (green) was used (1:1000, 1h). rabbits immunized with a KLH conjugated Nuclei were counterstained with Hoechst synthetic peptide between 1-30 amino acids from the N-terminal region of human ATG5. 33342 (blue) (10 μg/ml, 5 min). ATG5 immunoreactivity is localized to autophagic Dilution vacuoles in the cytoplasm of U251 cells. IF~~1:200 WB~~1:1000 IHC-P-Leica~~1:500 Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. Storage Maintain refrigerated at 2-8°C for up to 2 weeks. -
Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel
Published OnlineFirst October 15, 2013; DOI: 10.1158/1535-7163.MCT-13-0551 Molecular Cancer Cancer Biology and Signal Transduction Therapeutics Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel Yuko Maede1, Hiroyasu Shimizu4, Toru Fukushima2, Toshiaki Kogame1, Terukazu Nakamura3, Tsuneharu Miki4, Shunichi Takeda1, Yves Pommier5, and Junko Murai1,5 Abstract Clinical topoisomerase I (Top1) and II (Top2) inhibitors trap topoisomerases on DNA, thereby inducing protein-linked DNA breaks. Cancer cells resist the drugs by removing topoisomerase-DNA complexes, and repairing the drug-induced DNA double-strand breaks (DSB) by homologous recombination and nonhomol- ogous end joining (NHEJ). Because numerous enzymes and cofactors are involved in the removal of the topoisomerase-DNA complexes and DSB repair, it has been challenging to comprehensively analyze the relative contribution of multiple genetic pathways in vertebrate cells. Comprehending the relative contribution of individual repair factors would give insights into the lesions induced by the inhibitors and genetic determinants of response. Ultimately, this information would be useful to target specific pathways to augment the therapeutic activity of topoisomerase inhibitors. To this end, we put together 48 isogenic DT40 mutant cells deficient in DNA repair and generated one cell line deficient in autophagy (ATG5). Sensitivity profiles were established for three clinically relevant Top1 inhibitors (camptothecin and the indenoisoquinolines LMP400 and LMP776) and three Top2 inhibitors (etoposide, doxorubicin, and ICRF-193). Highly significant correlations were found among Top1 inhibitors as well as Top2 inhibitors, whereas the profiles of Top1 inhibitors were different from those of Top2 inhibitors. -
IL-1 Secretion Innate T Cell Responses Through Effects On
Autophagy Regulates IL-23 Secretion and Innate T Cell Responses through Effects on IL-1 Secretion This information is current as Celia Peral de Castro, Sarah A. Jones, Clíona Ní Cheallaigh, of September 24, 2021. Claire A. Hearnden, Laura Williams, Jan Winter, Ed C. Lavelle, Kingston H. G. Mills and James Harris J Immunol 2012; 189:4144-4153; Prepublished online 12 September 2012; doi: 10.4049/jimmunol.1201946 Downloaded from http://www.jimmunol.org/content/189/8/4144 Supplementary http://www.jimmunol.org/content/suppl/2012/09/12/jimmunol.120194 Material 6.DC1 http://www.jimmunol.org/ References This article cites 48 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/189/8/4144.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 24, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Autophagy Regulates IL-23 Secretion and Innate T Cell Responses through Effects on IL-1 Secretion Celia Peral de Castro,*,† Sarah A. -
The Association of ATG16L1 Variations with Clinical Phenotypes of Adult-Onset Still’S Disease
G C A T T A C G G C A T genes Article The Association of ATG16L1 Variations with Clinical Phenotypes of Adult-Onset Still’s Disease Wei-Ting Hung 1,2, Shuen-Iu Hung 3 , Yi-Ming Chen 4,5,6 , Chia-Wei Hsieh 6,7, Hsin-Hua Chen 6,7,8 , Kuo-Tung Tang 5,6,7 , Der-Yuan Chen 9,10,11,* and Tsuo-Hung Lan 1,5,12,13,* 1 Institute of Clinical Medicine, National Yang-Ming Chiao Tung University, Taipei 11221, Taiwan; [email protected] 2 Department of Medical Education, Taichung Veterans General Hospital, Taichung 40705, Taiwan 3 Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan; [email protected] 4 Department of Medical Research, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] 5 School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan; [email protected] 6 Rong Hsing Research Center for Translational Medicine & Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung 40227, Taiwan; [email protected] (C.-W.H.); [email protected] (H.-H.C.) 7 Division of Allergy, Immunology, and Rheumatology, Taichung Veterans General Hospital, Taichung 40705, Taiwan 8 Department of Industrial Engineering and Enterprise Information, Tunghai University, Taichung 40705, Taiwan 9 Translational Medicine Laboratory, Rheumatology and Immunology Center, China Medical University Hospital, Taichung 40447, Taiwan 10 Rheumatology and Immunology Center, China Medical University Hospital, Taichung 40447, Taiwan Citation: Hung, W.-T.; Hung, S.-I.; 11 School of Medicine, China Medical University, Taichung 40447, Taiwan Chen, Y.-M.; Hsieh, C.-W.; Chen, 12 Tsao-Tun Psychiatric Center, Ministry of Health and Welfare, Nantou 54249, Taiwan H.-H.; Tang, K.-T.; Chen, D.-Y.; Lan, 13 Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli 35053, Taiwan T.-H. -
Diet, Autophagy, and Cancer: a Review
1596 Review Diet, Autophagy, and Cancer: A Review Keith Singletary1 and John Milner2 1Department of Food Science and Human Nutrition, University of Illinois, Urbana, Illinois and 2Nutritional Science Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland Abstract A host of dietary factors can influence various cellular standing of the interactions among bioactive food processes and thereby potentially influence overall constituents, autophagy, and cancer. Whereas a variety cancer risk and tumor behavior. In many cases, these of food components including vitamin D, selenium, factors suppress cancer by stimulating programmed curcumin, resveratrol, and genistein have been shown to cell death. However, death not only can follow the stimulate autophagy vacuolization, it is often difficult to well-characterized type I apoptotic pathway but also can determine if this is a protumorigenic or antitumorigenic proceed by nonapoptotic modes such as type II (macro- response. Additional studies are needed to examine autophagy-related) and type III (necrosis) or combina- dose and duration of exposures and tissue specificity tions thereof. In contrast to apoptosis, the induction of in response to bioactive food components in transgenic macroautophagy may contribute to either the survival or and knockout models to resolve the physiologic impli- death of cells in response to a stressor. This review cations of early changes in the autophagy process. highlights current knowledge and gaps in our under- (Cancer Epidemiol Biomarkers Prev 2008;17(7):1596–610) Introduction A wealth of evidence links diet habits and the accompa- degradation. Paradoxically, depending on the circum- nying nutritional status with cancer risk and tumor stances, this process of ‘‘self-consumption’’ may be behavior (1-3). -
Activation of Lysosomal Function in the Course of Autophagy Via Mtorc1 Suppression and Autophagosome-Lysosome Fusion
npg Activation of lysosomal function in autophagy Cell Research (2013) 23:508-523. 508 © 2013 IBCB, SIBS, CAS All rights reserved 1001-0602/13 $ 32.00 npg ORIGINAL ARTICLE www.nature.com/cr Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion Jing Zhou1, Shi-Hao Tan1, 2, Valérie Nicolas3, 4, Chantal Bauvy4, 5, Nai-Di Yang1, Jianbin Zhang1, Yuan Xue6, Patrice Codogno4, 5, Han-Ming Shen1, 2 1Department of Physiology, Yong Loo Lin School of Medicine and Saw Swee Hock School of Public Health, National University of Singapore, Singapore 117597; 2NUS Graduate School for Integrative Sciences and Engineering National University of Singapore, Singapore 117597; 3Microscopy Facility-IFR-141-IPSIT, rue JB Clément, 92296 Châtenay-Malabry, France; 4University Paris- Sud, Orsay, France; 5INSERM U984, 92296 Châtenay-Malabry, France; 6Reed College, Portland, OR 97202, USA Lysosome is a key subcellular organelle in the execution of the autophagic process and at present little is known whether lysosomal function is controlled in the process of autophagy. In this study, we first found that suppression of mammalian target of rapamycin (mTOR) activity by starvation or two mTOR catalytic inhibitors (PP242 and To- rin1), but not by an allosteric inhibitor (rapamycin), leads to activation of lysosomal function. Second, we provided evidence that activation of lysosomal function is associated with the suppression of mTOR complex 1 (mTORC1), but not mTORC2, and the mTORC1 localization to lysosomes is not directly correlated to its regulatory role in lysosomal function. Third, we examined the involvement of transcription factor EB (TFEB) and demonstrated that TFEB acti- vation following mTORC1 suppression is necessary but not sufficient for lysosomal activation. -
The Bacterial Peptidoglycan-Sensing Molecules NOD1 and NOD2 Promote CD8 + Thymocyte Selection
The Bacterial Peptidoglycan-Sensing Molecules NOD1 and NOD2 Promote CD8 + Thymocyte Selection This information is current as Marianne M. Martinic, Irina Caminschi, Meredith O'Keeffe, of September 24, 2021. Therese C. Thinnes, Raelene Grumont, Steve Gerondakis, Dianne B. McKay, David Nemazee and Amanda L. Gavin J Immunol published online 15 February 2017 http://www.jimmunol.org/content/early/2017/02/15/jimmun ol.1601462 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2017/02/15/jimmunol.160146 Material 2.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 24, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published February 15, 2017, doi:10.4049/jimmunol.1601462 The Journal of Immunology The Bacterial Peptidoglycan-Sensing Molecules NOD1 and NOD2 Promote CD8+ Thymocyte Selection Marianne M. Martinic,*,1 Irina Caminschi,†,‡,2 Meredith O’Keeffe,†,2 Therese C. Thinnes,* Raelene Grumont,†,2 Steve Gerondakis,†,2 Dianne B. -
Following Cytochrome C Release, Autophagy Is Inhibited During Chemotherapy-Induced Apoptosis by Caspase 8–Mediated Cleavage of Beclin 1
Published OnlineFirst March 28, 2011; DOI: 10.1158/0008-5472.CAN-10-4475 Cancer Therapeutics, Targets, and Chemical Biology Research Following Cytochrome c Release, Autophagy Is Inhibited during Chemotherapy-Induced Apoptosis by Caspase 8–Mediated Cleavage of Beclin 1 Hua Li1, Peng Wang1, Quanhong Sun2, Wen-Xing Ding2, Xiao-Ming Yin2, Robert W. Sobol1,4, Donna B. Stolz3, Jian Yu2, and Lin Zhang1 Abstract Autophagy is an evolutionarily conserved stress response mechanism that often occurs in apoptosis-defective cancer cells and can protect against cell death. In this study, we investigated how apoptosis and autophagy affect each other in cancer cells in response to chemotherapeutic treatment. We found that specific ablation of the proapoptotic function of cytochrome c, a key regulator of mitochondria-mediated apoptosis, enhanced autophagy following chemotherapeutic treatment. Induction of autophagy required Beclin 1 and was associated with blockage of Beclin 1 cleavage by caspase 8 at two sites. To investigate the role of Beclin 1 cleavage in the suppression of autophagy and cell survival, a caspase-resistant mutant of Beclin 1 was knocked into HCT116 colon cancer cells. Beclin 1 mutant knockin resulted in markedly increased autophagy and improved long-term cell survival after chemotherapeutic treatment but without affecting apoptosis and caspase activation. Furthermore, Beclin 1 mutant tumors were significantly less responsive to chemotherapeutic treatment than were wild-type tumors. These results show that chemotherapy-induced apoptosis inhibits autophagy at the execution stage subsequent to cytochrome c release through caspase 8–mediated cleavage of Beclin 1. If apoptosis fails to execute, autophagy is unleashed due to lack of Beclin 1 cleavage by caspases and can contribute to cancer cell survival and therapeutic resistance.